Type 2 diabetes mellites (T2DM) is a complex disease and involves multiple pathophysiologic defects, which require a combination of multiple pharmacological approaches. The combination of sodium-glucose cotransporter type 2 inhibitor (SGLT-2i) and dipeptidyl peptidase-4 inhibitor (DPP-4i) has a strong rationale for two drugs exert complementary glucose-lowering effects. This combination is appealing, considering benefits such as better glycemic control, weight reduction, and improvement in cardio-renal outcomes without increasing the risk of hypoglycemia. 1,2 In this regard, Boehringer Ingelheim India and Docplexus have organized a multi-specialty panel discussion on 20 th November 2020 from 03:00 PM IST onwards. In this webinar, the expert panel ( Dr. A.
Ramachandran , Dr. Mala Dharmalingam , and Dr. C. K. Ponde ) will share their insights on the role of SGLT-2i + DPP-4i…
